查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1423670

到 2030 年血流感染检测市场预测：按产品类型、病原体类型、测试、技术、最终用户和地区进行的全球分析

Bloodstream Infection Testing Market Forecasts to 2030 - Global Analysis By Product Type, By Pathogen Type, Testing, Technology, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，2023 年全球血流感染检测市场规模为 60.9 亿美元，预计在预测期内复合年增长率为 9.3%，到 2030 年将达到 113.5 亿美元。

血流感染检测涉及旨在识别血流中微生物病原体的诊断程序。此测试使用多种技术，包括血液培养和分子生物学技术，来检测引起全身感染的细菌、病毒和真菌。这种检测在早期发现、确定适当的治疗策略和防止感染疾病传播方面发挥关键作用，极大地影响了全世界的患者照护和公共卫生。

根据世界上最大的医学图书馆美国国家医学图书馆的数据，血流感染疾病(BSI) 是世界上疾病和死亡的主要原因。 BSI 的发生率随着时间的推移而增加，每 10 万人中有 122 至 220 例。

全球血流感染疾病呈上升趋势

全球血流感染疾病（BSI）的惊人成长正成为血流传染病检查市场的强大动力。这种激增是由于抗生素抗药性增加、侵入性医疗程序以及更容易受到感染疾病的人口老化等因素造成的。对快速准确识别致病病原体的需求不断增长，推动了快速分子检测和自动化血液培养系统等先进诊断技术的市场发展。此外，人们对医疗保健相关感染 (HAI) 的认识不断提高，促使医院和诊所投资强大的 BSI 检测通讯协定，进一步推动市场扩张。

先进诊断技术带来的高成本

先进的诊断技术提供了更快、更准确的血流感染检测，但其高昂的价格是市场的主要抑制因素。这些先进的测试通常需要昂贵的设备、专业技术人员和复杂的工作流程，增加了医疗保健提供者和患者的成本。这可能会限制在资源有限的环境中进行检测，阻碍普及并抑制其对患者照护的潜在益处。

意识提升

提高医疗保健专业人员的认识是血流感染检测市场的关键机会。目前，许多医疗保健专业人员对最新的检测方法和早期检测 BSI 的紧迫性缺乏足够的了解。透过教育医生、护士和其他医务人员透过先进的检测进行快速识别和治疗的好处，市场可以释放巨大的成长潜力，有效地利用这一利润丰厚的机会，并促进市场扩张。

资料安全问题

血流感染测试严重依赖数位资料，因此容易受到网路攻击。骇客可以窃取敏感的患者资讯或操纵测试结果，可能影响诊断并伤害患者。这引发了对资料隐私、对测试准确性的信心以及潜在法律影响的担忧，从而限制了市场扩张。

COVID-19 的影响：

COVID-19 的爆发对血流感染检测产生了重大影响。医疗机构在优先考虑 COVID-19 检测资源方面面临挑战，这可能会降低对血流感染疾病常规检测的兴趣。此外，感染控制的变化、患者数量的增加和医疗保健实践使检测设施的能力紧张。疫情期间血流传染病检查的延迟和减少影响了及时诊断和治疗，可能会影响患者的治疗结果，并需要调整检测策略和医疗保健服务。

预计设备部分在预测期内将是最大的

由于血液感染疾病的盛行率日益增加，设备领域预计将占据市场上最大的市场占有率。自动化血液培养系统、分子诊断平台和质谱仪在快速识别病原体方面发挥着至关重要的作用。此外，设备技术的不断进步，例如灵敏度和特异性的提高，增强了其主导地位，使其成为血流感染检测市场占有率的主要贡献者。

诊断实验室领域预计在预测期内复合年增长率最高

由于人们对预防保健意识的不断提高和对诊断服务的需求不断增长，诊断测试行业有望实现显着增长。诊断技术的进步带来了更准确、更有效率的检测方法，吸引了更多的患者。此外，越来越多的慢性病需要定期监测，增加了对诊断中心服务的需求。此外，COVID-19 大流行凸显了便利、高效的诊断设施的重要性，并促进了全球诊断中心的扩张。

占比最高的地区

北美在血流感染检测市场的主导地位得益于其先进的医疗基础设施和对研发的大量投资。此外，主要市场参与者的存在、行业和研究机构之间的合作以及强大的法律规范都有助于市场的成长。此外，创新诊断技术的积极采用以及对感染控制重要性的日益认识也正在加强北美在确保最大市场占有率的地位。

复合年增长率最高的地区：

由于快速的都市化、医疗保健支出的增加以及先进医疗技术的普及，预计亚太地区将显着增长。此外，人口成长、健康问题意识增强以及政府支持医疗基础设施发展的努力也促成了这一趋势。凭藉新兴的中产阶级和不断发展的医疗保健系统，亚太地区为医疗保健和诊断等各个行业的市场扩张提供了巨大的机会。

免费客製化服务

订阅此报告的客户可以存取以下免费自订选项之一：

  • 公司简介
    • 其他市场参与者的综合分析（最多 3 家公司）
    • 主要企业SWOT分析（最多3家企业）
  • 区域分割
    • 根据客户兴趣对主要国家的市场估计、预测和复合年增长率（註：基于可行性检查）
  • 竞争基准化分析
    • 根据产品系列、地理分布和策略联盟对主要企业基准化分析

目录

第一章执行摘要

第二章 前言

  • 概述
  • 相关利益者
  • 调查范围
  • 调查方法
    • 资料探勘
    • 资料分析
    • 资料检验
    • 研究途径
  • 调查来源
    • 主要调查来源
    • 二次调查来源
    • 先决条件

第三章市场趋势分析

  • 促进因素
  • 抑制因素
  • 机会
  • 威胁
  • 产品分析
  • 技术分析
  • 最终用户分析
  • 新型冠状病毒感染疾病（COVID-19）的影响

第4章波特五力分析

  • 供应商的议价能力
  • 买方议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争公司之间的敌对关係

第五章全球血流感染检测市场：依产品类型

  • 装置
    • 全自动血液培养系统
    • 聚合酶连锁反应（PCR）装置
  • 消耗品
    • 血液培养瓶
    • 试剂
  • 软体
    • 资料分析软体
    • 报告及解释软体

第六章全球血流感染检测市场：依病原体类型

  • 细菌性血流感染疾病
  • 霉菌血流感染疾病
  • 病毒性血流感染疾病

第七章全球血流感染检测市场：通过测试

  • 血液培养测试
    • 常规血液培养
    • 自动血液培养
  • 分子诊断
    • 聚合酶炼式反应 (PCR)
    • 核酸扩增技术（NAAT）
  • 微生物检测
  • 免疫学测试

第八章全球血流感染检测市场：依技术分类

  • 常规培养技术
  • 质谱
  • 微阵列技术
  • 下一代定序（NGS）
  • 其他技术

第九章全球血流感染检测市场：依最终用户分类

  • 医院和诊所
  • 诊断实验室
  • 学术研究所
  • 即时检测
  • 其他最终用户

第十章全球血流感染检测市场：按地区

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 其他欧洲国家
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东和非洲

第十一章 主要进展

  • 合约、伙伴关係、协作和合资企业
  • 收购和合併
  • 新产品发布
  • 业务扩展
  • 其他关键策略

第十二章 公司简介

  • Abbott Laboratories
  • Accelerate Diagnostics
  • Becton, Dickinson and Company（BD）
  • Biocartis
  • BioMerieux
  • Bio-Rad Laboratories
  • Bruker Corporation
  • Cepheid
  • Danaher Corporation
  • DiaSorin
  • GenMark Diagnostics
  • Grifols
  • Hologic, Inc.
  • Luminex Corporation
  • Molzym
  • OpGen
  • Qiagen
  • Roche Diagnostics
  • Sysmex Corporation
  • Thermo Fisher Scientific
Product Code: SMRC24904

According to Stratistics MRC, the Global Bloodstream Infection Testing Market is accounted for $6.09 billion in 2023 and is expected to reach $11.35 billion by 2030 growing at a CAGR of 9.3% during the forecast period. Bloodstream infection testing involves diagnostic procedures aimed at identifying microbial pathogens in the bloodstream. This testing utilizes various techniques, including blood cultures and molecular methods, to detect bacteria, viruses, or fungi causing systemic infections. It plays a crucial role in early identification, guiding appropriate treatment decisions and preventing the spread of infections, significantly impacting patient care and public health on a worldwide scale.

According to the U.S. National Library of Medicine, world's largest medical library, Bloodstream Infections (BSIs) are a leading global cause of disease and mortality. The incidence of BSIs has grown over time and the rates ranges from 122 to 220 cases per 100,000 people.

Market Dynamics:

Driver:

Rising cases of bloodstream infections worldwide

The alarming rise in bloodstream infections (BSIs) across the globe is acting as a potent fuel for the bloodstream infection testing market. This surge is attributed to factors like increasing antibiotic resistance, invasive medical procedures and an aging population that is more susceptible to infections. This growing demand for rapid and precise identification of causative pathogens is driving the market for advanced diagnostic technologies like rapid molecular tests and automated blood culture systems. Additionally, heightened awareness about healthcare-associated infections (HAIs) is prompting hospitals and clinics to invest in robust BSI testing protocols, further propelling the market's expansion.

Restraint:

High costs associated with advanced diagnostic technologies

Advanced diagnostic technologies offer faster and more accurate bloodstream infection testing, their high price tag acts as a major market restraint. These sophisticated tests often require expensive equipment, specialized technicians, and complex workflows, driving up costs for both healthcare providers and patients. This can limit their accessibility in resource-constrained settings and discourage their widespread adoption, hindering the potential benefits they bring to patient care.

Opportunity:

Awareness among healthcare professionals

A crucial opportunity lies in raising awareness among healthcare professionals within the bloodstream infection testing market. Currently, many practitioners lack sufficient knowledge about the latest testing methods or the urgency of early BSI detection. By educating doctors, nurses and other medical staff on the rapid identification and treatment benefits of advanced testing, the market can unlock significant growth potential, which can effectively tap into this lucrative opportunity and drive market expansion.

Threat:

Data security concerns

Bloodstream infection testing relies heavily on digital data, making it vulnerable to cyberattacks. Hackers could steal sensitive patient information or manipulate test results, impacting diagnoses and potentially harming patients. This raises concerns about data privacy, trust in test accuracy and potential legal repercussions that limit market expansion.

Covid-19 Impact:

The COVID-19 pandemic significantly impacted bloodstream infection testing. Medical facilities faced challenges in prioritizing resources for COVID-19 testing, potentially reducing attention to routine testing for bloodstream infections. Additionally, infection control measures, increased patient loads, and altered healthcare practices strained laboratory capacities. Delayed or reduced testing for bloodstream infections during the pandemic might have affected timely diagnosis and treatment, potentially impacting patient outcomes and necessitating adaptations in testing strategies and healthcare delivery.

The instrument segment is expected to be the largest during the forecast period

The instrument segment is poised to secure the largest market share in the market due to the increasing prevalence of bloodstream infections. Automated blood culture systems, molecular diagnostic platforms, and mass spectrometers play pivotal roles in identifying pathogens swiftly. Additionally, continuous advancements in instrument technologies, such as improved sensitivity and specificity, bolster their prominence, making them the leading contributor to the market share for bloodstream infection testing.

The diagnostics laboratories segment is expected to have the highest CAGR during the forecast period

The diagnostics laboratories segment is poised for significant growth due to increased awareness of preventive healthcare and amplified demand for diagnostic services. Technological advancements in diagnostics have led to more accurate and efficient testing methods, attracting more patients. Additionally, the rising prevalence of chronic diseases necessitates regular monitoring, boosting the need for diagnostic center services. Moreover, the COVID-19 pandemic emphasized the importance of accessible and efficient diagnostic facilities, fostering the expansion of diagnostics centers globally.

Region with largest share:

North America's dominance in the bloodstream infection testing market is owing to its advanced healthcare infrastructure and significant investments in research and development. Moreover, the presence of key market players, collaborations between industry and research institutions, and robust regulatory frameworks contribute to market growth. Additionally, the region's proactive adoption of innovative diagnostic technologies and heightened awareness about the importance of infection control further solidify North America's position in securing the largest market share.

Region with highest CAGR:

The Asia-Pacific region is positioned for significant growth due to rapid urbanization, increasing healthcare spending and expanding access to advanced medical technologies. Additionally, a growing population, rising awareness about health issues, and government initiatives supporting healthcare infrastructure development contribute to this trajectory. With a burgeoning middle class and evolving healthcare systems, the Asia-Pacific region presents immense opportunities for market expansion across various industries, including healthcare and diagnostics.

Key players in the market

Some of the key players in Bloodstream Infection Testing Market include Abbott Laboratories, Accelerate Diagnostics, Becton, Dickinson and Company (BD), Biocartis, BioMerieux, Bio-Rad Laboratories, Bruker Corporation, Cepheid, Danaher Corporation, DiaSorin, GenMark Diagnostics, Grifols, Hologic, Inc., Luminex Corporation, Molzym, OpGen, Qiagen, Roche Diagnostics, Sysmex Corporation and Thermo Fisher Scientific.

Key Developments:

In October 2023, Biocartis Group NV (the 'Company' or 'Biocartis'), an innovative molecular diagnostics company and APIS Assay Technologies Ltd. ('APIS'), a private UK based company specializing in molecular diagnostics, today announced the expansion of their partnership1 to include the commercialization of the APIS ESR1 Mutations Kit through Biocartis' worldwide commercial network.

In October 2023, Oxford Nanopore Technologies plc ("Oxford Nanopore"), the company delivering a new generation of nanopore-based molecular sensing technology, and bioMerieux SA, a world leader in the field of in vitro diagnostics ("IVD") announced that bioMerieux is making an immediate £70M investment in Oxford Nanopore.

Product Types Covered:

  • Instruments
  • Consumables
  • Services

Pathogen Types Covered:

  • Bacterial Bloodstream Infections
  • Fungal Bloodstream Infections
  • Viral Bloodstream Infections

Testings Covered:

  • Blood Culture Test
  • Molecular Diagnostics
  • Microbiological Testing
  • Immunological Testing

Technologies Covered:

  • Conventional Culture Technology
  • Mass Spectrometry
  • Microarray Technology
  • Next-Generation Sequencing (NGS)
  • Other Technologies

End Users Covered:

  • Hospitals and Clinics
  • Diagnostic Laboratories
  • Academic and Research Institutes
  • Point-of-Care Testing
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 Technology Analysis
  • 3.8 End User Analysis
  • 3.9 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Bloodstream Infection Testing Market, By Product Type

  • 5.1 Introduction
  • 5.2 Instruments
    • 5.2.1 Automated Blood Culture Systems
    • 5.2.2 Polymerase Chain Reaction (PCR) Instruments
  • 5.3 Consumables
    • 5.3.1 Blood Culture Bottles
    • 5.3.2 Reagents
  • 5.4 Software
    • 5.4.1 Data Analysis Software
    • 5.4.2 Reporting and Interpretation Software

6 Global Bloodstream Infection Testing Market, By Pathogen Type

  • 6.1 Introduction
  • 6.2 Bacterial Bloodstream Infections
  • 6.3 Fungal Bloodstream Infections
  • 6.4 Viral Bloodstream Infections

7 Global Bloodstream Infection Testing Market, By Testing

  • 7.1 Introduction
  • 7.2 Blood Culture Test
    • 7.2.1 Conventional Blood Culture
    • 7.2.2 Automated Blood Culture
  • 7.3 Molecular Diagnostics
    • 7.3.1 Polymerase Chain Reaction (PCR)
    • 7.3.2 Nucleic Acid Amplification Techniques (NAAT)
  • 7.4 Microbiological Testing
  • 7.5 Immunological Testing

8 Global Bloodstream Infection Testing Market, By Technology

  • 8.1 Introduction
  • 8.2 Conventional Culture Technology
  • 8.3 Mass Spectrometry
  • 8.4 Microarray Technology
  • 8.5 Next-Generation Sequencing (NGS)
  • 8.6 Other Technologies

9 Global Bloodstream Infection Testing Market, By End User

  • 9.1 Introduction
  • 9.2 Hospitals and Clinics
  • 9.3 Diagnostic Laboratories
  • 9.4 Academic and Research Institutes
  • 9.5 Point-of-Care Testing
  • 9.6 Other End Users

10 Global Bloodstream Infection Testing Market, By Geography

  • 10.1 Introduction
  • 10.2 North America
    • 10.2.1 US
    • 10.2.2 Canada
    • 10.2.3 Mexico
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 UK
    • 10.3.3 Italy
    • 10.3.4 France
    • 10.3.5 Spain
    • 10.3.6 Rest of Europe
  • 10.4 Asia Pacific
    • 10.4.1 Japan
    • 10.4.2 China
    • 10.4.3 India
    • 10.4.4 Australia
    • 10.4.5 New Zealand
    • 10.4.6 South Korea
    • 10.4.7 Rest of Asia Pacific
  • 10.5 South America
    • 10.5.1 Argentina
    • 10.5.2 Brazil
    • 10.5.3 Chile
    • 10.5.4 Rest of South America
  • 10.6 Middle East & Africa
    • 10.6.1 Saudi Arabia
    • 10.6.2 UAE
    • 10.6.3 Qatar
    • 10.6.4 South Africa
    • 10.6.5 Rest of Middle East & Africa

11 Key Developments

  • 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 11.2 Acquisitions & Mergers
  • 11.3 New Product Launch
  • 11.4 Expansions
  • 11.5 Other Key Strategies

12 Company Profiling

  • 12.1 Abbott Laboratories
  • 12.2 Accelerate Diagnostics
  • 12.3 Becton, Dickinson and Company (BD)
  • 12.4 Biocartis
  • 12.5 BioMerieux
  • 12.6 Bio-Rad Laboratories
  • 12.7 Bruker Corporation
  • 12.8 Cepheid
  • 12.9 Danaher Corporation
  • 12.10 DiaSorin
  • 12.11 GenMark Diagnostics
  • 12.12 Grifols
  • 12.13 Hologic, Inc.
  • 12.14 Luminex Corporation
  • 12.15 Molzym
  • 12.16 OpGen
  • 12.17 Qiagen
  • 12.18 Roche Diagnostics
  • 12.19 Sysmex Corporation
  • 12.20 Thermo Fisher Scientific

List of Tables

  • Table 1 Global Bloodstream Infection Testing Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Bloodstream Infection Testing Market Outlook, By Product Type (2021-2030) ($MN)
  • Table 3 Global Bloodstream Infection Testing Market Outlook, By Instruments (2021-2030) ($MN)
  • Table 4 Global Bloodstream Infection Testing Market Outlook, By Automated Blood Culture Systems (2021-2030) ($MN)
  • Table 5 Global Bloodstream Infection Testing Market Outlook, By Polymerase Chain Reaction (PCR) Instruments (2021-2030) ($MN)
  • Table 6 Global Bloodstream Infection Testing Market Outlook, By Consumables (2021-2030) ($MN)
  • Table 7 Global Bloodstream Infection Testing Market Outlook, By Blood Culture Bottles (2021-2030) ($MN)
  • Table 8 Global Bloodstream Infection Testing Market Outlook, By Reagents (2021-2030) ($MN)
  • Table 9 Global Bloodstream Infection Testing Market Outlook, By Software (2021-2030) ($MN)
  • Table 10 Global Bloodstream Infection Testing Market Outlook, By Data Analysis Software (2021-2030) ($MN)
  • Table 11 Global Bloodstream Infection Testing Market Outlook, By Reporting and Interpretation Software (2021-2030) ($MN)
  • Table 12 Global Bloodstream Infection Testing Market Outlook, By Pathogen Type (2021-2030) ($MN)
  • Table 13 Global Bloodstream Infection Testing Market Outlook, By Bacterial Bloodstream Infections (2021-2030) ($MN)
  • Table 14 Global Bloodstream Infection Testing Market Outlook, By Fungal Bloodstream Infections (2021-2030) ($MN)
  • Table 15 Global Bloodstream Infection Testing Market Outlook, By Viral Bloodstream Infections (2021-2030) ($MN)
  • Table 16 Global Bloodstream Infection Testing Market Outlook, By Testing (2021-2030) ($MN)
  • Table 17 Global Bloodstream Infection Testing Market Outlook, By Blood Culture Test (2021-2030) ($MN)
  • Table 18 Global Bloodstream Infection Testing Market Outlook, By Conventional Blood Culture (2021-2030) ($MN)
  • Table 19 Global Bloodstream Infection Testing Market Outlook, By Automated Blood Culture (2021-2030) ($MN)
  • Table 20 Global Bloodstream Infection Testing Market Outlook, By Molecular Diagnostics (2021-2030) ($MN)
  • Table 21 Global Bloodstream Infection Testing Market Outlook, By Polymerase Chain Reaction (PCR) (2021-2030) ($MN)
  • Table 22 Global Bloodstream Infection Testing Market Outlook, By Nucleic Acid Amplification Techniques (NAAT) (2021-2030) ($MN)
  • Table 23 Global Bloodstream Infection Testing Market Outlook, By Microbiological Testing (2021-2030) ($MN)
  • Table 24 Global Bloodstream Infection Testing Market Outlook, By Immunological Testing (2021-2030) ($MN)
  • Table 25 Global Bloodstream Infection Testing Market Outlook, By Technology (2021-2030) ($MN)
  • Table 26 Global Bloodstream Infection Testing Market Outlook, By Conventional Culture Technology (2021-2030) ($MN)
  • Table 27 Global Bloodstream Infection Testing Market Outlook, By Mass Spectrometry (2021-2030) ($MN)
  • Table 28 Global Bloodstream Infection Testing Market Outlook, By Microarray Technology (2021-2030) ($MN)
  • Table 29 Global Bloodstream Infection Testing Market Outlook, By Next-Generation Sequencing (NGS) (2021-2030) ($MN)
  • Table 30 Global Bloodstream Infection Testing Market Outlook, By Other Technologies (2021-2030) ($MN)
  • Table 31 Global Bloodstream Infection Testing Market Outlook, By End User (2021-2030) ($MN)
  • Table 32 Global Bloodstream Infection Testing Market Outlook, By Hospitals and Clinics (2021-2030) ($MN)
  • Table 33 Global Bloodstream Infection Testing Market Outlook, By Diagnostic Laboratories (2021-2030) ($MN)
  • Table 34 Global Bloodstream Infection Testing Market Outlook, By Academic and Research Institutes (2021-2030) ($MN)
  • Table 35 Global Bloodstream Infection Testing Market Outlook, By Point-of-Care Testing (2021-2030) ($MN)
  • Table 36 Global Bloodstream Infection Testing Market Outlook, By Other End Users (2021-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.